m 6 A RNA modifications: Key regulators of normal and malignant hematopoiesis.

Autor: Sommerkamp P; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany. Electronic address: Pia.sommerkamp@embl.de., Brown JA; Institute for Cancer Genetics, Columbia University, New York, NY., Haltalli MLR; Wellcome-Medical Research Council Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK., Mercier FE; Lady Davis Institute for Medical Research, Department of Medicine, McGill University, Montreal, Quebec, Canada., Vu LP; Terry Fox Laboratory, British Columbia Cancer Research Centre, Vancouver, BC, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada., Kranc KR; Laboratory of Haematopoietic Stem Cell & Leukaemia Biology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Jazyk: angličtina
Zdroj: Experimental hematology [Exp Hematol] 2022 Jul; Vol. 111, pp. 25-31. Date of Electronic Publication: 2022 Apr 27.
DOI: 10.1016/j.exphem.2022.04.006
Abstrakt: Post-transcriptional RNA modifications determine RNA fate by influencing numerous processes such as translation, decay and localization. One of the most abundant RNA modifications is N 6 -methyladenoside (m 6 A), which has been shown to be important in healthy as well as malignant hematopoiesis. Several proteins representing key players in m 6 A RNA biology, such as m 6 A writers, erasers and readers, were recently reported to be essential for hematopoietic stem cell (HSC) function. In leukemia, expression of m 6 A regulators has been shown to be increased, opening up potential opportunities for therapeutic exploitation by targeting them in blood malignancies. These recent discoveries were the focus of the Fall 2021 International Society for Experimental Hematology New Investigators webinar. We review here the latest findings in the field of mRNA modifications in normal and malignant hematopoiesis and how this might open up novel therapeutic options.
Competing Interests: Conflict of interest disclosure The authors declare no competing interests.
(Copyright © 2022 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: